Research programme: JNK pathway inhibitors - Pharmascience
Alternative Names: AEG 3482Latest Information Update: 02 Jun 2011
At a glance
- Originator Aegera Therapeutics
- Class Small molecules; Sulfonamides; Sulfones; Sulfoxides; Thiadiazoles
- Mechanism of Action JNK mitogen-activated protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cancer; Diabetic neuropathies; Neuropathic pain; Peripheral nervous system diseases
Most Recent Events
- 25 Mar 2008 A lead compound from this programme has entered clinical development
- 16 Mar 2007 Aegera Therapeutics initiates an accelerated screening programme to identify replacement compound(s) for AEG 33783
- 11 Apr 2006 Data presented at the 231st ACS National Meeting (231st-ACS-2006) have been added to the Neurological disorders pharmacodynamics section